-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Generic drugs have important economic and social benefits in reducing medical expenditures, improving the availability of medicines, and improving the level of medical services
.
It is understood that China's generic drug industry is highly valued and is heavily supported by national industrial policies
.
In recent years, the state has successively introduced a number of policies to encourage the development and innovation of the generic drug industry, such as the "Announcement on the Quality and Efficacy Consistency Evaluation of Generic Drugs", "Opinions on Deepening the Reform of the Medical Security System", "Regarding Development Industrial policies such as the "Announcement on the Evaluation of the Quality and Efficacy Consistency of Generic Drugs for Chemical Injections" Policy Interpretation provide clear and broad market prospects for the development of the generic drug industry, and provide enterprises with a good production and operation environment
.
Data show that China's generic drug market has developed rapidly in the past ten years, with a scale of nearly 500 billion yuan
.
From the perspective of the pharmaceutical market structure, most of China's pharmaceutical companies currently focus on generic drugs, and generic drugs are also the mainstream
.
According to statistics, in 2020, generic drugs will account for 63% of the domestic drug market, and the market share of generic drugs will continue to increase
.
In addition, statistics show that among nearly 5,000 pharmaceutical companies, the total number of drug approval documents has reached 189,000, and generic drugs account for 95% of prescriptions
.
China's generic drug products were first dominated by oral solid preparations with low technical barriers.
Now, through mergers and acquisitions and cooperation, they are gradually migrating to injections, sustained and controlled release, inhalants, and biological analogues, raising technical barriers through differentiated competition
.
It is expected that the high-difficulty generic drugs will remain a blue ocean field in the future, and the combination of generic and innovative drugs is an inevitable trend
.
China's generic drug market is huge, but from the current point of view, there are still some problems with generic drugs
.
For example, the quality standards of generic drugs are relatively low; the product quality of pharmaceutical companies is relatively low and cannot meet market demand; the supply of cheap generic drugs is chronically short; the generic drug industry has relatively few companies with R&D and production capabilities
.
In order to better promote the development of the generic drug industry and meet people's drug demand, China still needs to continuously improve the quality of generic drugs
.
It is understood that in recent years, my country has also made a lot of efforts to improve the quality of generic drugs.
.
For example, the consistency evaluation policy for generic drugs implemented since 2016 is accelerating the change of the pattern of generic drugs in China
.
According to the industry, the advancement of consistency evaluation is a powerful measure to ensure the uniformity of China's drug quality and safety level and industry standards, and it will promote the increase of industry concentration
.
In addition, China also supports the development and use of high-quality generic drugs and promotes the substitution of generic drugs by improving medical insurance payment standards and drug bidding procurement mechanisms
.
Continuously improving industry policies are conducive to improving industry standards and drug quality and safety levels, and creating a healthy and good environment and institutional guarantees for high-quality pharmaceutical companies
.
Although under the influence of policies such as "4+7" volume purchase, medical insurance control fees, and two-invoice system, generic drugs are facing significant downward pressure on product sales and prices.
Some companies have begun to adjust the company's product layout and abandon part of the generic drug business to adapt to Market development
.
However, some analysts pointed out that “supporting innovation will not change the fact that generic drugs will still be the mainstay of patients in China for several years
.
In the future, generic drugs will still be the mainstay, and there will still be a broad market because patient needs are the fundamental driving force
.
" Another person said, “Innovation, challenge, generic drugs, and traditional Chinese medicine are the four major focuses of the industry in the next 10 years
.
The status of generic drugs will not change, but for the development of generic drugs, the person said that they are optimistic about the development of domestic pharmaceutical companies and foreign companies.
Cooperation prospects
.
.
It is understood that China's generic drug industry is highly valued and is heavily supported by national industrial policies
.
In recent years, the state has successively introduced a number of policies to encourage the development and innovation of the generic drug industry, such as the "Announcement on the Quality and Efficacy Consistency Evaluation of Generic Drugs", "Opinions on Deepening the Reform of the Medical Security System", "Regarding Development Industrial policies such as the "Announcement on the Evaluation of the Quality and Efficacy Consistency of Generic Drugs for Chemical Injections" Policy Interpretation provide clear and broad market prospects for the development of the generic drug industry, and provide enterprises with a good production and operation environment
.
Data show that China's generic drug market has developed rapidly in the past ten years, with a scale of nearly 500 billion yuan
.
From the perspective of the pharmaceutical market structure, most of China's pharmaceutical companies currently focus on generic drugs, and generic drugs are also the mainstream
.
According to statistics, in 2020, generic drugs will account for 63% of the domestic drug market, and the market share of generic drugs will continue to increase
.
In addition, statistics show that among nearly 5,000 pharmaceutical companies, the total number of drug approval documents has reached 189,000, and generic drugs account for 95% of prescriptions
.
China's generic drug products were first dominated by oral solid preparations with low technical barriers.
Now, through mergers and acquisitions and cooperation, they are gradually migrating to injections, sustained and controlled release, inhalants, and biological analogues, raising technical barriers through differentiated competition
.
It is expected that the high-difficulty generic drugs will remain a blue ocean field in the future, and the combination of generic and innovative drugs is an inevitable trend
.
China's generic drug market is huge, but from the current point of view, there are still some problems with generic drugs
.
For example, the quality standards of generic drugs are relatively low; the product quality of pharmaceutical companies is relatively low and cannot meet market demand; the supply of cheap generic drugs is chronically short; the generic drug industry has relatively few companies with R&D and production capabilities
.
In order to better promote the development of the generic drug industry and meet people's drug demand, China still needs to continuously improve the quality of generic drugs
.
It is understood that in recent years, my country has also made a lot of efforts to improve the quality of generic drugs.
.
For example, the consistency evaluation policy for generic drugs implemented since 2016 is accelerating the change of the pattern of generic drugs in China
.
According to the industry, the advancement of consistency evaluation is a powerful measure to ensure the uniformity of China's drug quality and safety level and industry standards, and it will promote the increase of industry concentration
.
In addition, China also supports the development and use of high-quality generic drugs and promotes the substitution of generic drugs by improving medical insurance payment standards and drug bidding procurement mechanisms
.
Continuously improving industry policies are conducive to improving industry standards and drug quality and safety levels, and creating a healthy and good environment and institutional guarantees for high-quality pharmaceutical companies
.
Although under the influence of policies such as "4+7" volume purchase, medical insurance control fees, and two-invoice system, generic drugs are facing significant downward pressure on product sales and prices.
Some companies have begun to adjust the company's product layout and abandon part of the generic drug business to adapt to Market development
.
However, some analysts pointed out that “supporting innovation will not change the fact that generic drugs will still be the mainstay of patients in China for several years
.
In the future, generic drugs will still be the mainstay, and there will still be a broad market because patient needs are the fundamental driving force
.
" Another person said, “Innovation, challenge, generic drugs, and traditional Chinese medicine are the four major focuses of the industry in the next 10 years
.
The status of generic drugs will not change, but for the development of generic drugs, the person said that they are optimistic about the development of domestic pharmaceutical companies and foreign companies.
Cooperation prospects
.
